

## DAFTAR PUSTAKA

1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int (Suppl)*. 2013;3:1–150.
2. Suwitra K. Penyakit Ginjal Kronik. In: Setiati S, Alwi I, Sudoyo AW, K. MSi, Setiyohadi B, Syam AF, editors. *Buku Ajar Ilmu Penyakit Dalam*. VI. Jakarta. Interna Publishing, 2015. p. 348–57.
3. Kuznik A, Mardekian J, Tarasenko L. Evaluation of cardiovascular disease burden and therapeutic goal attainment in US adults with chronic kidney disease: an analysis of national health and nutritional examination survey data, 2001-2010. *BMC Nephrol*. 2013 Jun 27;14:132. doi: 10.1186/1471-2369-14-132. PMID: 23802885; PMCID: PMC3701605.
4. Indonesian Renal Registry. 10th Report Of Indonesian Renal Registry. 2017. p.1-40
5. Leifheit-Nestler M, Haffner D. Paracrine Effects of FGF23 on the Heart. *Front Endocrinol (Lausanne)*. 2018 May 28;9:278. doi: 10.3389/fendo.2018.00278. PMID: 29892269; PMCID: PMC5985311.
6. de Albuquerque Suassuna PG, Sanders-Pinheiro H, de Paula RB. Uremic Cardiomyopathy: A New Piece in the Chronic Kidney Disease-Mineral and Bone Disorder Puzzle. *Front Med (Lausanne)*. 2018 Jul 24;5:206. doi: 10.3389/fmed.2018.00206. PMID: 30087898; PMCID: PMC6066558.
7. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutiérrez OM, Aguilon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J,

- Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-O M, Kusek JW, Keane MG, Wolf M. FGF23 induces left ventricular hypertrophy. *J Clin Invest*. 2011 Nov;121(11):4393-408. doi: 10.1172/JCI46122. Epub 2011 Oct 10. PMID: 21985788; PMCID: PMC3204831.
8. Gutiérrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. *Circulation*. 2009 May 19;119(19):2545-52. doi: 10.1161/CIRCULATIONAHA.108.844506. Epub 2009 May 4. PMID: 19414634; PMCID: PMC2740903.
  9. Bakri, S. Disertasi : Interaksi variasi genetik I/D gen angiotensin converting enzyme, hipertensi, dan transformasi growth factor- $\beta$ 1 pada pathogenesis hipertrofi ventrikel kiri. Program Pascasarjana Universitas Hasanuddin. Makassar, 2004,p: 1-41.
  10. Zou D, Wu W, He Y, Ma S, Gao J. The role of klotho in chronic kidney disease. *BMC Nephrol*. 2018 Oct 22;19(1):285. doi: 10.1186/s12882-018-1094-z. PMID: 30348110; PMCID: PMC6198535.
  11. Semba RD, Cappola AR, Sun K, Bandinelli S, Dalal M, Crasto C, Guralnik JM, Ferrucci L. Plasma klotho and cardiovascular disease in adults. *J Am Geriatr Soc*. 2011 Sep;59(9):1596-601. doi: 10.1111/j.1532-5415.2011.03558.x. Epub 2011 Aug 24. PMID: 21883107; PMCID: PMC3486641.
  12. Seifert ME, de Las Fuentes L, Ginsberg C, Rothstein M, Dietzen DJ, Cheng SC, Ross W, Windus D, Dávila-Román VG, Hruska KA. Left ventricular mass progression despite stable blood pressure and kidney function in stage 3 chronic kidney disease. *Am J Nephrol*.

- 2014;39(5):392-9. doi: 10.1159/000362251. Epub 2014 May 6. PMID: 24818573; PMCID: PMC4066883.
13. Yang K, Wang C, Nie L, Zhao X, Gu J, Guan X, Wang S, Xiao T, Xu X, He T, Xia X, Wang J, Zhao J. Klotho Protects Against Indoxyl Sulphate-Induced Myocardial Hypertrophy. *J Am Soc Nephrol*. 2015 Oct;26(10):2434-46. doi: 10.1681/ASN.2014060543. Epub 2015 Mar 24. PMID: 25804281; PMCID: PMC4587686.
  14. Gosse P. Left ventricular hypertrophy--the problem and possible solutions. *J Int Med Res*. 2005;33 Suppl 1:3A-11A. doi: 10.1177/14732300050330S102. PMID: 16222895.
  15. Cacciapuoti F. Molecular mechanisms of left ventricular hypertrophy (LVH) in systemic hypertension (SH)-possible therapeutic perspectives. *J Am Soc Hypertens*. 2011 Nov-Dec;5(6):449-55. doi: 10.1016/j.jash.2011.08.006. Epub 2011 Oct 20. PMID: 22015318.
  16. Kannel WB, Cobb J. Left ventricular hypertrophy and mortality--results from the Framingham Study. *Cardiology*. 1992;81(4-5):291-8. doi: 10.1159/000175819. PMID: 1301257.
  17. Garbi M. The general principles of echocardiography. In: *The EAE Textbook of Echocardiography*. Oxford university press,2011.p1-4
  18. Solomon SD, Wu JC, Gillam L. Echocardiography. In: *Braunwald's Heart Disease*. 11th Ed. Elsevier, 2019. p. 173-90
  19. Rohilla A. Cardiac hypertrophy: A review on pathogenesis and treatment. *Journal of Pharmaceuti Scie Drug Res*. 2012; 4(3):164-167
  20. Garcia JA, Incerpi EK. Factors and mechanisms involved in left ventricular hypertrophy and the anti-hypertrophic role of nitric oxide. *Arq Bras Cardiol*. 2008 Jun;90(6):409-16. English, Portuguese. doi: 10.1590/s0066-782x2008000600010. PMID: 18592095.

21. Di Lullo L, Gorini A, Russo D, Santoboni A, Ronco C. Left Ventricular Hypertrophy in Chronic Kidney Disease Patients: From Pathophysiology to Treatment. *Cardiorenal Med.* 2015 Oct;5(4):254-66. doi: 10.1159/000435838. Epub 2015 Jul 15. PMID: 26648942; PMCID: PMC4662296.
22. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr.* 2015 Jan;28(1):1-39.e14. doi: 10.1016/j.echo.2014.10.003. PMID: 25559473.
23. Shimamura Y, Hamada K, Inoue K, Ogata K, Ishihara M, Kagawa T, Inoue M, Fujimoto S, Ikebe M, Yuasa K, Yamanaka S, Sugiura T, Terada Y. Serum levels of soluble secreted  $\alpha$ -Klotho are decreased in the early stages of chronic kidney disease, making it a probable novel biomarker for early diagnosis. *Clin Exp Nephrol.* 2012 Oct;16(5):722-9. doi: 10.1007/s10157-012-0621-7. Epub 2012 Mar 29. PMID: 22457086.
24. Kim HR, Nam BY, Kim DW, Kang MW, Han JH, Lee MJ, Shin DH, Doh FM, Koo HM, Ko KI, Kim CH, Oh HJ, Yoo TH, Kang SW, Han DS, Han SH. Circulating  $\alpha$ -klotho levels in CKD and relationship to progression. *Am J Kidney Dis.* 2013 Jun;61(6):899-909. doi: 10.1053/j.ajkd.2013.01.024. Epub 2013 Mar 27. PMID: 23540260.
25. Rotondi S, Pasquali M, Tartaglione L, Muci ML, Mandanici G, Leonangeli C, Sales S, Farcomeni A, Mazzaferro S. Soluble  $\alpha$ -Klotho Serum Levels in Chronic Kidney Disease.

- Int J Endocrinol. 2015;2015:872193. doi: 10.1155/2015/872193. Epub 2015 Mar 19. PMID: 25873958; PMCID: PMC4383388.
26. Seiler S, Wen M, Roth HJ, Fehrenz M, Flügge F, Herath E, Weihrauch A, Fliser D, Heine GH. Plasma Klotho is not related to kidney function and does not predict adverse outcome in patients with chronic kidney disease. *Kidney Int.* 2013 Jan;83(1):121-8. doi: 10.1038/ki.2012.288. Epub 2012 Aug 15. PMID: 22895520.
27. Xie J, Cha SK, An SW, Kuro-O M, Birnbaumer L, Huang CL. Cardioprotection by Klotho through downregulation of TRPC6 channels in the mouse heart. *Nat Commun.* 2012;3:1238. doi: 10.1038/ncomms2240. PMID: 23212367; PMCID: PMC3526952.
28. Bi X, Yang K, Zhang B, Zhao J. The Protective Role of Klotho in CKD-Associated Cardiovascular Disease. *Kidney Dis (Basel).* 2020 Nov;6(6):395-406. doi: 10.1159/000509369. Epub 2020 Aug 19. PMID: 33313060; PMCID: PMC7706511.
29. Liu Z, Zhou H, Chen X, Chen H, Wang Y, Wang T, Cai L, Hong Y, Ke H, Zheng J. Relationship between cFGF23/Klotho ratio and phosphate levels in patients with chronic kidney disease. *Int Urol Nephrol.* 2019 Mar;51(3):503-507. doi: 10.1007/s11255-019-02079-4. Epub 2019 Jan 28. PMID: 30689182.
30. Shibata K, Fujita S, Morita H, Okamoto Y, Sohmiya K, Hoshiga M, Ishizaka N. Association between circulating fibroblast growth factor 23,  $\alpha$ -Klotho, and the left ventricular ejection fraction and left ventricular mass in cardiology inpatients. *PLoS One.* 2013 Sep 9;8(9):e73184. doi: 10.1371/journal.pone.0073184. Erratum in: *PLoS One.* 2013;8(10). doi:10.1371/annotation/13086f84-18f2-4ea3-881a-0484b0c411ee. Erratum in: *PLoS One.* 2014;9(4):e93346. PMID: 24039882; PMCID: PMC3767778.

31. Abdallah E, Mosbah O, Khalifa G, Metwaly A, El-Bendary O. Assessment of the relationship between serum soluble Klotho and carotid intima-media thickness and left ventricular dysfunction in hemodialysis patients. *Kidney Res Clin Pract.* 2016 Mar;35(1):42-9. doi: 10.1016/j.krcp.2015.12.006. Epub 2016 Jan 21. PMID: 27069857; PMCID: PMC4811978.
32. Apostolović B, Cvetković T, Stefanović N, Apostolović S, Apostolović MA, Mitić B, Radovanović RV, Paunović K, Ignjatović A, Cvetković M, Stević N, Pavlović D. The predictive value of Klotho polymorphism, in addition to classical markers of CKD-MBD, for left ventricular hypertrophy in haemodialysis patients. *Int Urol Nephrol.* 2019 Aug;51(8):1425-1433. doi: 10.1007/s11255-019-02193-3. Epub 2019 Jun 11. PMID: 31187426.
33. Tanaka S, Fujita S, Kizawa S, Morita H, Ishizaka N. Association between FGF23,  $\alpha$ -Klotho, and Cardiac Abnormalities among Patients with Various Chronic Kidney Disease Stages. *PLoS One.* 2016 Jul 11;11(7):e0156860. doi: 10.1371/journal.pone.0156860. PMID: 27400031; PMCID: PMC4939955.
34. Kim HJ, Kang E, Oh YK, Kim YH, Han SH, Yoo TH, Chae DW, Lee J, Ahn C, Oh KH. The association between soluble klotho and cardiovascular parameters in chronic kidney disease: results from the KNOW-CKD study. *BMC Nephrol.* 2018 Mar 5;19(1):51. doi: 10.1186/s12882-018-0851-3. PMID: 29506503; PMCID: PMC5838864.
35. Wesseling-Perry K, Jüppner H. The osteocyte in CKD: new concepts regarding the role of FGF23 in mineral metabolism and systemic complications. *Bone.* 2013 Jun;54(2):222-9. doi: 10.1016/j.bone.2012.10.008. Epub 2012 Oct 16. PMID: 23079136; PMCID: PMC3582844.

36. Lorell BH, Carabello BA. Left ventricular hypertrophy: pathogenesis, detection, and prognosis. *Circulation*. 2000 Jul 25;102(4):470-9. doi: 10.1161/01.cir.102.4.470. PMID: 10908222.
37. Fourtounas C. Phosphorus metabolism in chronic kidney disease. *Hippokratia*. 2011 Jan;15(Suppl 1):50-2. PMID: 21897759; PMCID: PMC3139680.